These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31543285)

  • 1. Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
    Bhushan S; Ray RS; Prakash J; Singh GN
    Clin Ther; 2019 Nov; 41(11):2252-2262. PubMed ID: 31543285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefixime-associated acute generalized exanthematous pustulosis: Rare cases in India.
    Kumar V; Kalaiselvan V; Kumar AP; Saurabh A; Thota P; Sidhu S; Medhi B
    Indian J Pharmacol; 2018; 50(4):204-207. PubMed ID: 30505057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year.
    Singh P; Agrawal M; Hishikar R; Joshi U; Maheshwari B; Halwai A
    Indian J Pharmacol; 2017; 49(6):432-437. PubMed ID: 29674797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
    Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
    Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®.
    Ampadu HH; Hoekman J; de Bruin ML; Pal SN; Olsson S; Sartori D; Leufkens HG; Dodoo AN
    Drug Saf; 2016 Apr; 39(4):335-45. PubMed ID: 26754924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.
    Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A
    Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse reactions to contrast media: an analysis of spontaneous reports in the database of the pharmacovigilance programme of India.
    Kalaiselvan V; Sharma S; Singh GN
    Drug Saf; 2014 Sep; 37(9):703-10. PubMed ID: 25085041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous Adverse Drug Reaction Monitoring in a Tertiary Care Centre.
    Kaur K; Kanwal P; Goyal P; Singh P; Yakhmi S; Jain S; Kaushal S
    Curr Drug Saf; 2020; 15(3):215-221. PubMed ID: 32735525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report.
    Pai SA; Kshirsagar NA
    Indian J Med Res; 2016 Nov; 144(5):672-681. PubMed ID: 28361819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.
    Sharma PK; Misra AK; Gupta A; Singh S; Dhamija P; Pareek P
    Indian J Pharmacol; 2018; 50(5):273-278. PubMed ID: 30636831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.
    Alroobaea R; Rubaiee S; Hanbazazah AS; Jahrami H; Garbarino S; Damiani G; Wu J; Bragazzi NL
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):4074-4081. PubMed ID: 35731078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
    Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
    Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Status of documentation grading and completeness score for Indian individual case safety reports.
    Vivekanandan K; Rishi K; Prasad T; Arunabh T; Singh GN
    Indian J Pharmacol; 2015; 47(3):325-7. PubMed ID: 26069373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study.
    Goyal A; Singh H; Sehgal VK; Jayanthi CR; Munshi R; Bairy KL; Kumar R; Kaushal S; Kakkar AK; Ambwani S; Goyal C; Mazumdar G; Adhikari A; Das N; Stephy DJ; Thangaraju P; Dhasmana DC; Rehman SU; Chakrabarti A; Bhandare B; Badyal DK; Kaur I; Chandrashekar K; Singh J; Dhamija P; Sarangi SC; Gupta YK
    Indian J Med Res; 2017 Oct; 146(4):468-475. PubMed ID: 29434060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced tumoral disease: A global pharmacovigilance database analysis.
    Zelmat Y; Despas F
    Therapie; 2024; 79(2):189-197. PubMed ID: 38042752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective pharmacovigilance analysis of nonsteroidal anti-inflammatory drugs-induced chronic kidney disease.
    Swathi VS; Saroha S; Prakash J; Bhushan S
    Indian J Pharmacol; 2021; 53(3):192-197. PubMed ID: 34169903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database.
    Montastruc JL; Lafaurie M; de Canecaude C; Durrieu G; Sommet A; Montastruc F; Bagheri H
    Br J Clin Pharmacol; 2021 Nov; 87(11):4334-4340. PubMed ID: 33837554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.
    Piccinni C; Motola D; Marchesini G; Poluzzi E
    Diabetes Care; 2011 Jun; 34(6):1369-71. PubMed ID: 21515844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.